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Abstract—The remarkable growth of multi-platform genomic profiles has led to the challenge of multiomics data integration. In this
study, we present a novel network-based multiomics clustering founded on the Wasserstein distance from optimal mass transport. This
distance has many important geometric properties making it a suitable choice for application in machine learning and clustering. Our
proposed method of aggregating multiomics and Wasserstein distance clustering (aWCluster) is applied to breast carcinoma as well as
bladder carcinoma, colorectal adenocarcinoma, renal carcinoma, lung non-small cell adenocarcinoma, and endometrial carcinoma
from The Cancer Genome Atlas project. Subtypes were characterized by the concordant effect of mRNA expression, DNA copy
number alteration, and DNA methylation of genes and their neighbors in the interaction network. aWCluster successfully clusters all
cancer types into classes with significantly different survival rates. Also, a gene ontology enrichment analysis of significant genes in the
low survival subgroup of breast cancer leads to the well-known phenomenon of tumor hypoxia and the transcription factor ETS1 whose
expression is induced by hypoxia. We believe aWCluster has the potential to discover novel subtypes and biomarkers by accentuating
the genes that have concordant multiomics measurements in their interaction network, which are challenging to find without the
network inference or with single omics analysis.
Index Terms—aWCluster, multiomics integration, cancer network, Wasserstein distance, clustering.
F
1 INTRODUCTION
T HE molecular development of neoplasms occurs at a numberof genomic, transcriptomic and epigenomic scales. The ag-
gregation of multi-dimensional omics data potentially provides a
comprehensive view of the etiology of oncogenesis and tumor
progression at different molecular levels. Large scale cancer
genome projects, such as The Cancer Genome Atlas (TCGA)
project include an unprecedented amount of multi-dimensional
data to explore the entire spectrum of genomic abnormalities in
human cancer [1]. With the exponential growth of such data, the
great need to obtain an integrated view of multiomics interplay is
becoming ever more pressing.
Many sophisticated mathematical and statistical algorithms of
multiomics clustering have been proposed, yet the need for more
effective techniques to improve the clinical outcome prediction
remains a challenge [2]. The mutiomics integrative methods could
be primarily classified into two categories of early and late
integration. A late integration approach considers clustering each
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single omic data separately, then finding the consensus of these
clusterings [3], [4], [5], [6]. Such methods could result in loss
of information from signals that are weak in each omic and
they do not consider the interplay of different omic layers. A
more appealing integration focuses on building a model for an
earlier integration of multiomics followed by a single clustering
of the samples. This approach includes network-based methods
such as similarity network fusion (SNF) [7], Lemon-Tree for
module network inference [8] and, PARADIGM [9] as well as
matrix factorization methods such as non-negative matrix factor-
ization (NMF) [10], [11] and iCluster [12]. The ongoing effort of
multiomics integration have been successfully applied in cancer
research for the identification of cancer patients subtypes and
tumor molecular pattern [13], [14], [15], [16].
Our method of aggregating multiomics and Wasserstein dis-
tance clustering (aWCluster) considers a network-based integra-
tion of multiomics in early stage. The aWCluster integration
approach regards the gene expression of any transcript as a
biological function of the gene copy number alteration and DNA
methylation which can also be modulated in any level by the other
genes (gene products) in their protein-protein interaction (PPI)
network. Therefore, using the clustering approach of aWCluster
considers the PPI network of genes in representing the functional
concordance of the multiomics in their interaction network.
Amplification of oncogenes and deletion of tumor suppressors
give rise to malignant neoplasms [17]. Furthermore, epigenetic
aberrations caused by DNA methylation has a central role in tumor
progression [18]. Consequently, aWCluster’s approach for com-
bining the values of copy number alteration and DNA methylation
with gene expression in a network-based manner significantly
improves the accuracy in characterizing the genes that have an
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essential role in cancer progression. Our method of integration in
aWCluster is akin to CNAmet in aggregating the copy number,
methylation, and gene expression data [19]. However, CNAmet
does not consider the protein interaction network, clustering of
samples and it only focuses on binary values of multiomics which
could have sensitive dependency on thresholds.
In order to include the protein interaction network in aWClus-
ter, we consider the weighted network for each sample as the result
of an underlying stochastic process that is driven by interactions
among connected nodes. For each sample, we construct a dis-
tribution of integrative measures across the nodes of the network,
which is closely related to the invariant (stationary) measures of an
associated Markov chain. We employ these integrative measures to
cluster six cancer types from TCGA data. Our clustering method
in aWCluster is based on optimal mass transport (OMT) methods,
utilizing the 1-Wasserstein distance [20], also known as Earth
Mover’s Distance (EMD), applied to the invariant distributions of
integrative measures computed between samples [21]. We defined
the cost of calculating the Wasserstein distance based on the
shortest path between the genes in the (unweighted) PPI network.
Using the Wasserstein distance is not only a very natural way to
define the distance between distributions (assigned to samples) but
also results in a network-based distance for clustering the data.
The invariant measure of the Markov chain considered in this
work has an explicit closed formula which makes our method more
efficient and interpretable than the spectral clustering methods
used in other integrative methods such as SNF [7]. Also, our
network-based method is quite different from the sample similarity
approach in the iterative model of SNF; SNF does not consider the
protein interaction network nor the mechanistic interplay of mul-
tiomics layers. The difficulty of interpretability also occurs with
the latent variables in matrix factorization methods such as NMF
and iCluster [12]. Using the proposed aWCluster methodology,
we are able to identify the significant genes in the breast cancer
cluster with a significantly low survival rate. We further perform
gene ontology (GO) enrichment analysis on these genes utilizing
a curated bioinformatics database (MetaCore) to discover the
significantly correlated biological processes/pathways that could
be related to the high mortality in this cluster. Consequently, an
effective bridge between the biology of cancer and mathematical
techniques can bring about a comprehensive, meaningful and
predictive model of multiomics integration with identification of
biomarkers for cancer treatment.
We primarily applied aWCluster for subtype analysis and
biomarker identification in breast cancer. For validation pur-
poses, we also utilized aWCluster for survival analysis in bladder
urothelial carcinoma, colorectal adenocarcinoma, renal clear cell
carcinoma, lung non-small cell adenocarcinoma, and endometrial
carcinoma. Our breast cancer clustering result is concordant with
well-known PAM50 subtypes, however, it provides additional
heterogeneity within and across the subtypes. aWCluster is sig-
nificantly effective in predicting survival rates in all cancer types
and it facilitates the identification of the important driver genes
in each cluster, which in turn may allow researchers to glean new
therapeutic approaches from the results.
2 MATERIALS AND METHODS
We adopted methods from OMT [20], [22] to measure the simi-
larity of the integrative multiomics profiles between samples. To
this end, we calculated the 1-Wasserstein distance between the
probability distributions of the integrative measures assigned to the
samples. More precisely, we first derived the integrative measures
from the invariant measures of the stochastic matrix associated
with the PPI network (Fig. 1). The integrative measures aggregate
the gene expression, copy number alteration and methylation in a
network-based fashion. We then utilized the Wasserstein distance
to measure the similarity between every pair of distributions (π∗)
of integrative measures assigned to every two samples (Fig. 2).
Consequently, we applied these pair-wise Wasserstein distances to
perform the hierarchical clustering of the samples. In the following
section, we first discuss our integration method in aWCluster, then
we review the clustering of samples via 1-Wasserstein distance
using the protein interaction network. In fact, the interaction
network has been utilized in both integrating multiomics and
calculating the Wasserstein distances for the clustering purposes.
2.1 Constructing Sample Specific Integrative Measures
We applied our method to integrate the multiomics data of TCGA
breast carcinoma. The integrative measure is defined via the
mRNA expression (z-score of RNA Seq), copy number alteration
and methylation data of TCGA, and the PPI network from the
Human Protein Reference Database (HPRD, http://www.hprd.org)
[23]. The breast cancer TCGA data consists of mRNA expression
of 18,022 genes for 1,100 cases, copy number values of 15,213
genes for 1,080 cases and methylation of 15,585 genes in 741
cases. The intersection of all three data resulted in 7,737 genes and
726 samples. Moreover, this gene set has 3,426 genes in common
with HPRD in the largest connected component. Subsequently,
we applied aWCluster to aggregate all the three multiomics of
3,426 genes using their connected interaction network to cluster
726 samples. We further considered making the method compu-
tationally less expensive by limiting the genes with the ones only
in common with OncoKB (Precision Oncology Knowledge Base)
genes (http://oncokb.org/) which is discussed extensively in the
Supplementary Information. Similarly, the intersection of three
data types results in 8031 genes (311 in HPRD/ OncoKB) and
116 samples for bladder urothelial carcinoma , 9646 genes (535 in
HPRD/ OncoKB) and 195 samples for colorectal adenocarcinoma,
1399 genes (154 in HPRD/ OncoKB) and 80 samples for renal
clear cell carcinoma, 12936 genes (542 in HPRD OncoKB) and
416 samples for lung cancer, and 1426 genes (305 in HPRD) and
108 samples for endometrial carcinoma.
A given gene interaction network such as HPRD provides an
unweighted graph where nodes are genes and edges represent the
interaction among genes. We further constructed a weighted graph
by considering the gene interaction network as a Markov chain
[21]. Consider a gene i and its neighbor genes j ∈ N(i) in their
interaction network (here in HPRD) for a given sample. Let gek
denote the expression level of gene k in a given sample. The
principle of mass action allows us to compute the probability of
the interaction of gene i to gene j (pij) to be proportional to their
expression , i.e. pij ∝ (gei)(gej) [24]. By normalizing pij such
that
∑
j pij = 1, we have the stochastic matrix p of the Markov





The Markov chain given by Eq (1) reaches a stationary
distribution which is invariant under a right multiplication by p,
i.e. πp = π, [21]. Solving for the special stochastic matrix p
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Fig. 1: Workflow of aWCluster’s methodology: A. Network-based integration of multiomics (mRNA expression, DNA methylation
and copy number alteration) uses the PPI network (HPRD) to define the sample specific integrative measures. Integrative measures is
defined for each gene (of a specific sample) and is measuring the concordance of all three multiomics of the gene and its neighbors
in the interaction network. B. Network-based clustering of the samples by applying Wasserstein distance to the integrative measures
where the cost is the shortest path in the PPI network. Hierarchical clustering has been applied to the samples which are represented
as a vector of their distances to all others. C. The clustering is used for clinical outcome analysis such as survival rate and also GO
enrichment analysis for discovering biomarkers associated with each subtype.
defined by Eq (1), π has the explicit expression- for every gene i








where Z is a normalization factor forcing π to be a probability
distribution (
∑
π = 1). Note that this normalization is necessary
since we want to consider the invariant measure to be a probability
distribution over all genes for each specific sample. The invariant
measure defined by Eq (2), gives a value to each gene which is
not only dependent on the expression of the gene i, but also on the
expressions of its neighboring genes j ∈ N(i).
We have extended this invariant measure to the integrative
measure in order to consider copy number alteration and methy-
lation in addition to gene expression. Our approach roughly
follows that of CNAmet [19], however, our method is network
based. We characterize the genes that are up-regulated with
high expression, amplification and hypomethylation, and also
have many connections with similarly up-regulated genes in their
interaction network. Correspondingly, the integrative measures
identified genes that are down-regulated with low expression,
deletion and hypermethylation within their interaction network.
In fact, for TCGA data, the Spearman’s correlations between the
gene expression and the copy number alteration across the samples
are mostly significantly positive (see Fig. S3 of Supplementary
Information). Similarly, positive correlations exist between gene
expression and 1−methylation (one minus methylation). There-
fore, we considered the values of 1−methylation (which are
positive as methylation values are between 0 and 1) to calculate the
integrative measures in Eq (4). In CNAmet, the gene expression
(mean across all samples) values have been multiplied by binary
values assigned to copy number and methylation. In the proposed
aWCluster method, we utilized the actual normalized values of
copy number and methylation in the integrative measures assigned
to samples.
In order to define the integrative measure of gene i in the PPI
network, we first consider the invariant measure (Eq (2)) for each
of the single omics:




where ξ is any of the ge, cn, and me (which stands for gene
expression, copy number, and methylation respectively). Conse-
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Fig. 2: The integration of multiomics in aWCluster is network-based. We assigned an integrative measure to the nodes of the interaction
network using the network connectivity and the values of gene expression, copy number alteration and methylation. The integrative
measures define a weighted network for each sample. Wasserstein distance calculates the most efficient way to move the distribution of
integrative measure from one sample to another sample where the cost is the shortest path in the network. Here, we only show a small
network for the purpose of illustration.











Here, the scaling factor εi is defined based on the normalized








where di is the node degree of the gene i in the interaction
network.
In integrative measure formulation (Eq (4)), the multiplication
of omics’ invariants measures capture the network-based con-
cordance of gene expression with methylation and copy number
alteration. In addition, the scaling factor ε [19], accounts for the
concordance of copy number alteration and methylation.
For each sample, we calculated the vector π∗ = (πi∗)i=1,...,n
for all the genes in our data sets. We also added the normalization
factor Z in Eq (4) so that integrative measure of each sample forms
a probability distribution. We finally applied methods from OMT
[20] to find the distance between a pair of vectors of the form π∗
(Fig. 2) assigned to every two samples. In fact, we measured the
similarity between samples by finding the Wasserstein distance
between the distributions of the integrative measures assigned to
them, which we define in more detail in the following section.
Here, we also present an alternative closed form formula for an
integrative measure which is convenient for implementing. Let Adj
denote the adjacency matrix of our network, i. e., the n×n matrix
whose (i, j) entry is 1 if there is an edge (interaction) connecting
node (gene) i and node j, and 0 otherwise. The vector π∗ of















(Adj + In)× (me ◦ cn). (8)
In these expressions, ◦ denotes the component-wise (Hadamard)
product, whereas × is the standard matrix multiplication. Also, d
is the vector of all node degrees, 1 is all-ones vector, and In is the
n × n identity matrix. Here, every row of the matrix Adj + In is
divided by the corresponding component of d + 1.
2.2 Clustering via Wasserstein distance
aWCluster uses the theory of OMT to define distances among
samples. OMT is a rapidly developing area of research that
deals with the geometry of probability densities [20]. The subject
began with the work of Gaspard Monge in 1781 [25] who
formulated the problem of finding minimal transportation cost
to move a pile of soil (“deblais”), with mass density ρ0, to
an excavation (“remblais”), with a mass density ρ1. A relaxed
version of the problem was introduced by Leonid Kantorovich
in 1942 [26]. Let ρ0, ρ1 ∈ P (Ω) where Ω ⊆ RN and
P (Ω) = {ρ(x) :
∫
Ω ρ(x)dx = 1, ρ(x) ≥ 0}. The 1-Wasserstein
distance, also known as the Earth Mover’s Distance (EMD), is
defined as follows:
W1(ρ




‖x− y‖ dγ(x, y), (9)
where Γ(ρ0, ρ1) denotes the set of all couplings between ρ0 and
ρ1, that is the set of all joint probability measures γ on Ω ×
Ω whose marginals are ρ0 and ρ1. Here, the cost function of
the transportation is defined as the ground distance d(x, y) =
‖x− y‖.
This optimization problem has an analogous formulation on a
weighted graph (network). Let us consider a connected undirected
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graph G = (V, E) with n nodes in V and m edges in E . Given two
probability densities ρ0, ρ1 ∈ Rn on the graph, the EMD problem
seeks a joint distribution ρ ∈ Rn×n with marginals ρ0 and ρ1





















Here cij is the cost of moving unit mass from node i to node
j and is taken to be the minimum of the number of steps
(unweighted shortest path) to go from i to j, namely, c is the
ground metric on the graph. The minimum of this optimization
problem defines a metric W1 (the Earth Mover’s Distance) on the
space of probability densities on G. Note that this optimization
problem consists of n2 variables.
An alternative and computationally more efficient formulation
of the EMD (often called the Beckmann formulation [27]) is
defined by optimizing the flux vector m : Ω → RN in the
following manner:
W1(ρ








where ‖.‖ is the standard Euclidean distance based norm.
A graph-theoretic formulation of Eq (11) is as follows which
gives an alternative way to compute the EMD on the graph G:
W1(ρ




‖ui‖ | ρ0 − ρ1 −Du = 0
}
. (12)
On the graph G, the fluxes ui are defined on the m edges, and
D ∈ Rn×m denotes the incidence matrix of G with an assigned
orientation. More precisely, the incidence matrix D is a matrix
with rows and columns indexed by the vertices and edges of G
such that every entry (i, k) is equal to 1 if the vertex i is assigned
to be the head of the edge k and is equal to -1 if it is the tail of
k. Very importantly, note that the optimization problem in Eq (12)
depends on m variables, while the primal node based version of
OMT on a graph in Eq (10) depends on n × n variables. Thus
formula in Eq (12) is certainly much more efficient especially
when the graph is sparse, that is, m << n2.
aWCluster is implemented in MATLAB and the code
including a sample data set is publicly available in
https://github.com/mpouryah/aWCluster. For implementations of
Wasserstein distance in low dimensional data (< 1000 nodes
in network) we used the Rubner’s algorithm [28], and for larger
networks (> 1000 nodes) we applied CVX package [29] to solve
the optimization problem in Eq (11). The average computational
time required to compute distance between two samples on a
single CPU is 68 seconds for a network of 290 genes via Rubner’s
algorithm and is 278 seconds for a network of 3426 genes via CVX
algorithm. After calculating the pairwise EMD of samples in the
dataset, each sample is represented as a vector of its distances to all
other samples (its distance to itself is zero). We then applied the
hierarchical agglomerative clustering algorithm to these vectors.
To achieve a certain number of clusters, the hierarchy is cutoff
at the relevant depth. The optimal number of clusters can be
determined with several techniques. In the present work, we
chose the optimal number of cluster based on the homogeneity of
clusters measured by silhouette mean values [30]. The silhouette
value for each sample is a measure of how similar that sample is
to other samples in its own cluster compared to samples in other
clusters. The silhouette value for the sample i, s(i) is defined as:
s(i) := (b(i)− a(i))/(max(a(i), b(i)), (13)
where a(i) denotes the average distance of the sample i to
all samples within its own cluster (squared Euclidean distance
between sample vectors), and b(i) denotes the minimum average
distance of the sample i to samples of other clusters. Silhouette
values range from -1 to +1. A high silhouette value indicates
that the data are appropriately clustered. Therefore, we chose the
optimal number of clusters by analyzing the average silhouette
values of samples to make sure they stay close to 1.
We also compared the survival analysis in aWCluster to
alternative multiomics clustering methods of iCluster [12], SNF
[7], and CNAmet [19]. As we discussed earlier, the network-based
approach in SNF is quite different from aWCluster and it considers
the sample similarity network rather than the gene interaction
network. CNAmet primarily focuses on the integration step and
lets users define their own method to cluster the samples. Here,
we used CNAmet’s combination score (methylation and copy
number) multiplied with gene expression of samples to perform
the hierarchical clustering. We also compared our breast cancer
clustering results with the well-known PAM50 molecular subtypes
of breast cancer (Luminal A, Luminal B, HER2-enriched, Basal-
like, and Normal-like), which were first described in 2000 by
Perou et al. [31], [32], [33]. This classification begins with the
analysis of microarray expressions of 50 genes (known as the
“PAM50” gene signatures) to cluster breast tumors into one of
the subtypes. The results of these comparison is discussed further
in the following section.
3 RESULTS
We primarily applied aWCluster to TCGA breast cancer data
consisting of 3,426 genes and 726 samples. The hierarchical
clustering of 726 samples of TCGA breast cancer via aWCluster is
shown in Fig. 3(a). The Kaplan-Meier plot of the clusters’ survival
rate is illustrated in Fig. 3(b). The data has been truncated at 5
years, i.e. patients’ status is considered to be living (censoring)
if the death is after 5 year follow-up. The log-rank test indicates
a significantly different survival time between the four Kaplan-
Meier curves (p-value=0.0018). The number of clusters is chosen
based on the silhouette values we discussed previously in the
‘Materials and Methods’ section. Here, choosing three or four
clusters had a very small effect on the silhouette values, however,
clusters 1 and 2 (which are combined in the presence of three
clusters) have very different survival rates. Therefore, we chose
the number of clusters to be four.
We compared our clustering with the well-known PAM50
molecular subtypes of breast cancer (Luminal A, Luminal B,
HER2-enriched, Basal-like, and Normal-like). As shown in Ta-
ble 1, our clustering substantially recovers the major PAM50
subtypes (chi-squared test’s p-value  10−4) even though there
are only 19 of the PAM50 genes in the network utilized by
aWCluster. We have the PAM50 subtype classification for 649
out of 726 samples in the database. Clusters 3 and 4 significantly
distinguish Luminal A from the Basal-like subtype. Cluster 4 also
includes most of the Luminal B subtype. Moreover, many of the
Her2 enriched tumor types are in cluster 1 whereas the normal-like
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(a)
(b)
Fig. 3: (a) Hierarchical clustering of 726 samples using 3,426 genes via aWCluster. The first bar underneath the hierarchical clustering
corresponds to the PAM50 subtypes. The black color represents the samples whose PAM50 subtypes are not available. Furthermore,
the heatmaps represent the integrative measures, gene expression, copy number alteration, and methylation of 150 genes selected based
on ANOVA. Here, these top 150 genes are sorted (descending order) for cluster 1. The difference in the integrative measures between
clusters is visually detectable in the heatmap. Of note, the samples are ordered based on clustering via integrative measures and if we
started with one of these single omics we would not be able to achieve this clustering. We still see the pattern in the values of each
single omics especially for gene expression and copy number alteration, however, they are not as clear as the one with the integrative
values. (b) Display of survival rate using the Kaplan-Meier curves with respect to multiomics (aWCluster) and single omic subgroups of
TCGA breast carcinoma. Sample survival time (months) are plotted on the y-axis (truncated at 5 years), and the probability of survival
calculated according to the Kaplan-Meier method is plotted on the x-axis. The p-value (log-rank test) for mutiomics is significantly
lower than single omic subtypes. The number of clusters with each data type is chosen based on the silhouette mean value 13. In
aWCluster, Cluster 2∗ has a very low survival rate compared to the other three subgroups.
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subtype is clustered together with Luminal A tumors in cluster
3. Also, as we expected, the overall survival status of cluster 3
which mainly consists of the Luminal A subtype is higher than
cluster 4 which includes many of the Luminal B and Basal-like
subtypes (p-value=0.014). Despite this consistency, our clustering
provides additional heterogeneity within PAM50 subtypes which
is significantly more predictive of survival rates (Table 2). As
shown in Fig. 3(b), Cluster 2∗ in aWCluster has a significantly low
survival rate compared to the other three clusters. This Cluster of
53 samples mostly consist of Basal-like and Luminal B subtypes.
Fig. 3(a) shows the heatmap of integrative measures of 150
selected genes for 726 samples. The values of integrative measures
are visually distinguishable between clusters which assures the ac-
curacy of the clustering method. We utilized Analysis of Variance
(ANOVA) to choose 150 top genes that have significantly different
mean values of integrative measures across the four clusters. For
better visualization, we further reordered these 150 genes based
on the highest to lowest mean values in cluster 1. The highest
values of integrative measures in cluster 1 (which has many HER2-
enriched tumors) are by far ERBB2, GRB7, and PIK3C2A. Also,
these genes have very significantly different mean values across
the 4 clusters (after sorting based on ANOVA’s p-values). This
result is consistent with the known co-amplification of ERBB2 and
GRB7 in HER2-enriched breast cancer [34]. The complete list of
these 150 genes has been provided in S1 Dataset of Supplementary
Information. We also provided the heatmap of gene expression,
copy number alteration, and methylation in Fig. 3(a). We still see
the pattern in the values of each single omics, however, these
single omics patterns are not as clear as the one with the integrative
values.
In order to investigate the importance of integrating the mul-
tiomics in aWCluster, we compared aWCluster to clustering with
individual single omics (gene expression/ copy number alteration/
methylation). We applied the network-based invariant measures
given in Eq (2) which only depends on one single omics. As
shown in Fig. 3(b), single omic analysis mostly did not result in
significantly different survival clusters, but aWCluster had signif-
icant differences in survival rates. We also provide a complement
analysis by removing one of the three omics (Fig. 5). To this
end, we applied a multiplication of invariant measures in Eq (2)
for two of the omics. Consistent with single omics analysis, the
most predictive data type for survival analysis is mRNA expression
and clustering with DNA methylation and DNA copy number not
resulting in a predictive subgroups for survival rate.
We also repeated aWCluster to cluster TCGA breast cancer
data using the genes that are only included in the OncoKB
database to evaluate the robustness of the method. This smaller
network with 290 genes is computationally much more effi-
cient. The clustering of the 726 samples using this gene set is
significantly consistent with our previous clustering using the
3,426 genes (chi-squared test’s p-value  10−4 for contingency
Table S4 of Supplementary Information) indicating the robustness
of aWCluster’s methodology to preselection of genes. We included
the details of this clustering along with more clinical outcome
analysis in Supplementary Information.
For validation of aWCluster performance in other cancer types,
we applied our pipeline to five other cancer types using the
genes that each one shares with HPRD/ OncoKB in their largest
connected component of their network. The number of samples
for these five cancers are much smaller that breast cancer (with
the highest being 416 samples for lung cancer and the smallest
being 80 samples for renal carcinoma), and the number of clusters
remained two for these cancer types. The result in Fig. 4 shows the
generalizability of aWCluster in stratifying subgroups of patients
with different cancer type with regard to their survival outcome.
We also compared aWCluster to the alternative methods of
iCluster, SNF, and CNAmet. Unlike aWCluster, both iCluster and
SNF are dependent on hyperparameters in their method. iCluster is
less robust to the choice of hyperparameter (Lasso parameter) and
preselection of genes. Here, we compare the four methods with
the same set of genes. SNF and CNAmet are less computationally
expensive than iCluster and aWCluster but achieves a higher p-
value for log-rank test of survival rate. The log-rank p values
of these methods are provided in Table 2 for breast and lung
cancer. All four methods have substantially recovered the Luminal
A subtypes in breast cancer, yet aWCluster subtypes are more
similar to iCluster rather than to SNF and CNAmet.
We furthermore studied the immune subtypes of the TCGA
breast cancer samples provided in the paper [35]. Table 3 provides
the immune subtypes in our two largest clusters via aWCluster.
As shown in Table 3, cluster 3 recovers most of the inflammatory
immune subtype. This group was defined by Th17 and Th1 gene
elevation and lower level aneuploidy [35] and it has the best prog-
nosis among TCGA data. Likewise, our cluster 3 which consists of
mostly Luminal A, has a very good prognosis (Fig. 3(b)). Of note,
cluster 3 includes even more samples of inflammatory immune
subtype (81%) compared to the PAM50 Luminal A subtype (73%).
One of the advantages of aWCluster is its interpretability.
The integrative measures of aWCluster are defined explicitly for
all genes in the study. Therefore, we can investigate genes that
contribute the most in separating a specific cluster. Here, we are
interested in the GO enrichment analysis of the significant genes
in the clusters to see which biological processes/ pathways are
related to the clusters with distinguished survival rates in breast
cancer. As we see in Fig. 3(b), cluster 2 has the lowest survival
rate compared to all other clusters. We identified the genes that
have significantly different mean values in this cluster compared
to the other three clusters using the t-test. We chose 166 significant
genes (S2 Dataset in Supplementary Information) in cluster 2
based on the (t-test) Bonferroni corrected p-value less than 0.01.
We then performed a GO enrichment analysis of these genes via
MetaCore software (Thomson Reuters). MetaCore is an integrated
software based on a manually-curated database of molecular inter-
actions, molecular pathways, gene-disease associations, chemical
metabolism, and toxicity information. We discovered that the sig-
nificant genes in cluster 2 notably correspond with hypoxia. In the
top ten biological processes presented in Table 4, the first, second,
and also fifth processes are strongly correlated to hypoxia (p-value
 10−6) . Tumor hypoxia, a well-known phenomenon where
tumor cells have been deprived of oxygen, is a prominent issue
in tumor physiology and cancer treatment [36], [37]. Specifically,
hypoxia appears to be strongly associated with tumor malignancy,
resistance to treatment and the metastatic phenotype of cancer
[38], [39]. Performing similar analysis for choosing the significant
genes in the other three clusters, did not result in hypoxia as a top
biological process in the other GO enrichment analysis.
The protein/gene interaction network of these 166 genes is also
presented in Fig. 6. The network is very much connected which in-
dicates that many of these 166 genes are related to each other. The
three hub nodes, ETS1, AP-1, and STAT3 located within the nu-
cleus are highly connected to many other proteins in the network.
The hypoxia-inducible factor (HIF-1) is the principal transcription
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Fig. 4: Display of survival rate using the Kaplan-Meier curves for five TCGA cancer types. Sample survival time (months) are plotted
on the y-axis (truncated at 5 years), and the probability of survival calculated according to the Kaplan-Meier method is plotted on the
x-axis. The significant p-values (log-rank test) shows that aWCluster successfully stratifies patients of all cancer types into the groups
with significantly different survival rates.
factor related to hypoxia, and it has been demonstrated that HIF-1
activity is increased in various tumors relative to that found within
normal tissues [40], [41]. Along with HIF-1, members of the v-
ets erythroblastosis virus E26 oncogene homolog (ETS) family
transcription factors, most prominently the proto-oncogene ETS1,
participate in the upregulation of hypoxia-inducible genes [42].
Oikawa et al. [36] showed for the first time that ETS1 is induced
in the setting of hypoxia via the transcriptional activity of HIF-
1. Of note, increased expression of ETS1 is seen in a variety of
solid cancers including lung, colorectal, sarcoma, and squamous
cell carcinomas, and higher levels have correlated with a higher
incidence of lymph node metastasis and overall worse prognosis
[43]. This gene is also involved in tumor progression in breast
cancer, where in the setting of hypoxia, increased expression
by mammary epithelial cells contributes to aggressive tumor
phenotypes by activating the transcription of genes involved in
angiogenesis, extracellular matrix remodeling, cell adhesion, and
invasion [36], [44]. Moreover, increased expression of ETS1 is
associated with increased risk of recurrence and worse prognosis
in human breast cancers [45].
In addition, Activator Protein 1 (AP-1), another hub node in
our network of significant genes (Fig. 6) has also been identified
as a hypoxia-inducible transcription factor [46]. C-jun, a proto-
oncogene, encodes a major component of AP-1 transcription
factors, which are key regulators of immediate-early signals di-
recting cellular proliferation, differentiation, survival, and envi-
ronmental stress responses [47]. AP-1 appears to be involved
in the modulation of the apoptotic pathway and also plays a
protective role in cellular response to DNA damage [48], [49].
Piret et al. [50] demonstrated an AP-1 mediated protective role of
hypoxia against cell death induced by the chemotherapeutic agent
etoposide. Similarly, in the setting of hypoxia, an anti-apoptotic
role of AP-1 was seen in paclitaxel exposed breast cancer cells
TABLE 1: aWCluster subgroups are concordant with the PAM50
subtypes. The chi-squared test’s p-value 10−4 (after excluding
the normal subtype due to small counts). Cluster 3 includes most
of the Luminal A subtype, whereas cluster 4 consists of the Basal-
like and Luminal B subtypes.
PAM50 Cluster 1 Cluster 2∗ Cluster 3 Cluster 4 Total
Lum A 7 8 240 83 338
Lum B 11 18 32 69 130
Her 2 17 4 5 14 40
Basal 4 16 17 76 113
Normal 0 1 21 6 28
Total 39 47 315 248 649
[51].
Furthermore, STAT3 is another hub node in our network
and is included in the set of 166 significant genes related to
the subgroup with the worst survival. Hypoxia can induce the
activation of transcription 3 (STAT3) protein, with the hypoxia-
induced biochemical alterations likely contributing to drug resis-
tance under hypoxic conditions [52]. Notably, hypoxia-induced
STAT3 accelerates the accumulation of HIF-1 protein and has been
shown to prolong its half-life in solid tumor cells [53]. Moreover,
in a triple-negative breast cancer cell line, STAT3 has been shown
to play a key role in hypoxia-induced chemoresistance to the
chemotherapeutic agent cisplatin [54].
4 DISCUSSION
The complexity of cancer etiology, the advent of large scale
diverse genome-wide data, and the significant improvement in
mathematical/statistical data analysis tools has resulted in con-
siderable progress in the field of multiomics integration [55]. We
believe that in aggregating multiomics, it should be considered
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Fig. 5: Display of survival rate using the Kaplan-Meier curves with respect to excluding one of the three multiomics in TCGA breast
cancer. Sample survival time (months) are plotted on the y-axis (truncated at 5 years), and the probability of survival calculated
according to the Kaplan-Meier method is plotted on the x-axis. The number of clusters with each data type is chosen based on
the silhouette mean value. The p-value (log-rank test) for DNA copy number and methylation is significantly higher than two other
multiomics.
TABLE 2: We compared aWCluster to alternative methods of iCluster, SNF, CNAmet, and PAM50 subtypes for breast carcinoma and
lung non-small cell adenocarcinoma. The p-value (log-rank test) of aWCluster is significantly lower than the alternative methods.
Integration method aWCluster PAM50 CNAmet iCluster SNF
Breast Cancer 4.23× 10−3 6.05× 10−2 3.62× 10−1 2.23× 10−2 3.72× 10−2
Lung Cancer 7.3× 10−3 - 5.59× 10−1 3.28× 10−2 1.17× 10−1
Fig. 6: The protein (gene) interaction network of the significant genes for the subgroup with the worst survival outcome (via MetaCore).
The network includes the hub nodes ETS1 as well as AP-1 and STAT3 located within the nucleus.
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TABLE 3: Immune subtypes of breast cancer TCGA data in the
two largest clusters (via aWCluster). Cluster 3 which has a good
prognosis recovers most of the inflammatory immune subtype. The
percentages of each immune subtype in our clusters are included in
the table. The complete table including all four clusters is provided
in Table S5 of Supplementary Information.
Immune Subtype Cluster 3 Cluster 4 Total (all 4 clusters)
Wound healing 89 98 225
(40%) (44%) (31%)
IFN-γ domminant 107 127 271
(39%) (47%) (36%)
Inflammatory 113 21 139
(81%) (15%) (19%)
Lymphocyte depleted 27 22 61
(44%) (36%) (8%)
TGF-β dominant 18 5 26
(69%) (19%) (4%)
TABLE 4: Top 10 biological processes obtained from the gene
ontology enrichment analysis of the significant genes for the sub-
group with the worst survival outcome. Top biological processes
(first, second and also fifth) are strongly correlated with hypoxia.
Ranking Biological Processes
1 Response to decreased oxygen levels
2 Response to hypoxia
3 Regulation of cellular biosynthetic process
4 Cellular macromolecule metabolic process
5 Response to oxygen levels
6 Regulation of macromolecule biosynthetic process
7 Regulation of biosynthetic process
8 Positive regulation of macromolecule biosynthetic process
9 Positive regulation of cellular biosynthetic process
10 Positive regulation of nucleobase-containing compound
metabolic process
that cancer-related genes do not act individually, but within an
interaction network, which must be explicitly incorporated into the
integration procedure. Recent efforts in network-based analysis
of ‘omics’ allow identification of new disease genes, pathways
and rational drug targets that were not easily detectable by
isolated gene analysis [56]. The network based integration of
aWCluster considers the mRNA expression, DNA methylation,
and copy number alteration of the genes in their corresponding
neighborhoods of the interaction network. The concordance of
the mutiomic values for a gene and its neighbors in the network
results in a high integrative measure of the gene. aWCluster
defines the similarity measured among samples by the Wasserstein
distance between the distributions of the samples of the integrative
measures along the genes. Applying aWCluster to six cancer
types from TCGA data successfully clusters data with significantly
different survival rates. We showed that network-based integration
of all the genomic, transcriptomic, and epigenomic data increases
the information content and accuracy of the results more than any
of the single omics studies separately.
We were able to recover the well-known PAM50 subtypes in
breast cancer TCGA data and identified the inflammatory immune
subtype which has an improved prognosis. The immune subtype
analysis of TCGA data has been done through the characteristic
immuno-oncologic gene signatures [35]. The identification of the
inflammatory immune subgroup with increased survival in our
independent clustering results may support the existence of other
gene signatures in this subtype.
Our clustering results also reveal a subgroup of breast cancer
patients with substantially poor survival outcome. We performed
the GO enrichment analysis on the genes that have significantly
different values in this cluster compared to others. The analysis
discovered that this gene set is significantly related to the biolog-
ical process of hypoxia. Also, as we see in Fig. 6, the network
of these genes is very densely connected, with a hub node ETS1
which is a transcription factor included in the list of 166 significant
genes of the subgroup with the worst survival rate.
We should note that our methodology does not identify the
dominant etiology of the hypoxia subtype. In particular, these
cases may represent an evolution from states represented by
another cluster. Another limitation of the present work is that
we only consider an undirected form of the interaction network.
In addition to considering directionality, we previously studied
the type of control (e.g., activator and repressor in transcription
networks) in biological networks [57]. Accordingly, in future
work, we plan to include the effect of both the network direction
and regulation control type in our integrative measures.
In conclusion, we believe that the integration of multiomics/
biological data paves the way for precision medicine in treating
sophisticated diseases such as cancer. To this end, we proposed
a novel integrating method, based on the theory of optimal mass
transport, that allows for the interactive relationship among differ-
ent omics layers, and accurately clusters breast and lung cancer
samples with significantly different survival rates.
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